IQVIA (IQV) to Release Earnings on Thursday

IQVIA (NYSE:IQV) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect IQVIA to post earnings of $3.40 per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.84 EPS. On average, analysts expect IQVIA to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Performance

Shares of IQVIA stock opened at $239.67 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04. The firm’s 50-day simple moving average is $230.48 and its 200-day simple moving average is $207.51. The firm has a market cap of $40.82 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 2.45 and a beta of 1.36.

Analyst Ratings Changes

IQV has been the topic of several recent analyst reports. BMO Capital Markets initiated coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. UBS Group boosted their price target on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Truist Financial lifted their target price on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, Mizuho set a $266.00 price objective on IQVIA in a report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $251.06.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in the business. Measured Wealth Private Client Group LLC bought a new stake in IQVIA during the third quarter worth about $30,000. Johnson Financial Group Inc. acquired a new stake in IQVIA during the third quarter worth approximately $52,000. Wealth Watch Advisors INC acquired a new stake in IQVIA during the third quarter worth about $74,000. MUFG Securities EMEA plc acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $77,000. Finally, Ancora Advisors LLC raised its position in IQVIA by 17.9% in the third quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 79 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.